ABT ABBOTT LABORATORIES
Pharmaceutical Preparations · NYSE · SEC CIK 1800 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.0%
TTM net income YoY-66.4%
TTM EPS YoY-66.2%
Revenue 3-yr CAGR6.5%
Net income 3-yr CAGR-3.1%
Margins
Gross margin56.9%
Operating margin13.8%
Net margin9.7%
FCF margin14.0%
EBITDA margin17.0%
Returns
ROE9.2%
ROA4.9%
ROIC (approx.)7.1%
Asset turnover0.50x
Leverage & solvency
Liabilities / assets52.3%
Debt / equity0.61x
Current ratio1.45x
Interest coverage6.68x
Cash quality & payout
Operating cash flow / net income1.88x
Accruals ratio-4.3%
Payout ratio92.0%
Capex / revenue4.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $13.01B | $12.59B | $11.16B | $11.46B | $11.37B | $11.14B | $10.36B | $10.97B |
| Cost of revenue | $5.63B | $5.33B | $4.89B | $4.92B | $5.08B | $4.85B | $4.47B | $4.94B |
| Gross profit | $7.38B | $7.27B | $6.27B | $6.54B | $6.29B | $6.29B | $5.89B | $6.03B |
| R&D expense | $920.00M | $892.00M | $767.00M | $735.00M | $766.00M | $725.00M | $716.00M | $749.00M |
| SG&A expense | $4.27B | $4.03B | $3.74B | $3.13B | $3.05B | $3.09B | $3.06B | $2.91B |
| Operating income | $1.36B | $1.69B | $1.34B | $2.25B | $2.06B | $2.05B | $1.69B | $1.91B |
| Interest expense | $350.00M | $351.00M | $174.00M | $120.00M | $121.00M | $121.00M | $131.00M | $136.00M |
| Pretax income | $1.23B | $1.52B | $1.45B | $2.36B | $2.18B | $2.15B | $1.78B | $2.03B |
| Income tax | $311.00M | $596.00M | $372.00M | $582.00M | $536.00M | $371.00M | $453.00M | -$7.20B |
| Net income | $920.00M | $928.00M | $1.08B | $1.78B | $1.64B | $1.78B | $1.32B | $9.23B |
| EBITDA | $1.77B | $2.10B | $1.73B | $2.62B | $2.43B | $2.41B | $2.03B | $2.25B |
| EPS (basic) | 0.53 | 0.53 | 0.62 | — | 0.94 | 1.02 | 0.76 | — |
| EPS (diluted) | 0.53 | 0.53 | 0.61 | — | 0.94 | 1.01 | 0.76 | — |
| Dividends declared per share | 0.63 | 0.63 | 0.63 | 0.63 | 0.59 | 0.59 | 0.59 | 0.59 |
| Weighted avg. shares (diluted) | 1.74B | 1.74B | 1.75B | — | 1.75B | 1.75B | 1.75B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.05B | $5.10B | $6.80B | $8.52B | $7.51B | $6.95B | $6.53B | $7.62B |
| Short-term investments | $246.00M | $499.00M | $492.00M | $417.00M | $222.00M | $331.00M | $312.00M | $351.00M |
| Receivables | $9.03B | $8.60B | $8.21B | $7.93B | $8.14B | $7.97B | $7.33B | $6.92B |
| Inventory | $7.34B | $7.32B | $6.99B | $6.49B | $6.71B | $6.95B | $6.64B | $6.19B |
| Current assets | $23.50B | $24.52B | $25.51B | $26.00B | $24.84B | $24.47B | $23.15B | $23.66B |
| PP&E, net | $12.88B | $12.81B | $12.38B | $11.82B | $11.50B | $11.39B | $10.93B | $10.66B |
| Goodwill | $32.64B | $35.24B | $35.22B | $24.04B | $23.97B | $23.95B | $23.36B | $23.11B |
| Intangibles | $19.59B | $17.21B | $17.88B | $5.53B | $5.60B | $5.92B | $6.26B | $6.65B |
| Total assets | $108.25B | $109.22B | $110.43B | $86.71B | $84.18B | $84.00B | $81.45B | $81.41B |
| Current liabilities | $16.15B | $17.81B | $18.38B | $16.50B | $14.58B | $13.44B | $13.00B | $14.16B |
| Short-term debt | $1.71B | $3.00B | $4.41B | $3.03B | $1.34B | $507.00M | $506.00M | $1.50B |
| Long-term debt | $29.45B | $29.60B | $29.64B | $9.90B | $11.60B | $12.93B | $12.74B | $12.62B |
| Total debt | $31.16B | $32.61B | $34.05B | $12.93B | $12.94B | $13.44B | $13.24B | $14.12B |
| Total liabilities | $56.62B | $57.45B | $57.73B | $33.94B | $32.92B | $33.17B | $32.38B | $33.51B |
| Shareholders' equity | $51.03B | $51.11B | $52.06B | $52.13B | $50.95B | $50.56B | $48.81B | $47.66B |
| Net debt | $27.11B | $27.50B | $27.24B | $4.41B | $5.43B | $6.49B | $6.71B | $6.51B |
| Cash flow statement | ||||||||
| Operating cash flow | $1.74B | $2.49B | $1.31B | $3.31B | $2.79B | $2.05B | $1.42B | $2.87B |
| Capital expenditure | $513.00M | $497.00M | $399.00M | $689.00M | $496.00M | $502.00M | $484.00M | $720.00M |
| Free cash flow | $1.22B | $1.99B | $916.00M | $2.63B | $2.29B | $1.54B | $933.00M | $2.15B |
| Investing cash flow | -$385.00M | -$673.00M | -$20.32B | -$913.00M | -$457.00M | -$582.00M | -$470.00M | -$866.00M |
| Financing cash flow | -$2.40B | -$3.52B | $17.31B | -$1.40B | -$1.76B | -$1.10B | -$2.06B | -$1.86B |
| Depreciation & amortization | $415.00M | $402.00M | $381.00M | $370.00M | $371.00M | $357.00M | $336.00M | $342.00M |
| Stock-based compensation | $137.00M | $168.00M | $317.00M | $113.00M | $120.00M | $142.00M | $289.00M | $111.00M |
| Dividends paid | $1.09B | $1.10B | $1.10B | $1.03B | $1.03B | $1.03B | $1.03B | $958.00M |
| Share buybacks | $11.00M | $1.04B | $180.00M | $302.00M | $305.00M | $6.00M | $280.00M | $315.00M |
Free plan shows the latest 8 periods; Pro shows all 75 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.